CVAC, SBNY and CRMD Are Among After Hour Movers
Seeking AlphaApr 17 17:01 ET
Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Sutro Biopharma, Inc. (NASDAQ:STRO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased t
Simply Wall StApr 5 07:21 ET
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Dow JonesApr 3 10:16 ET
Express News | Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18
Moomoo 24/7Apr 3 09:32 ET
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
Dow JonesApr 3 08:34 ET
Express News | JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Moomoo 24/7Apr 3 08:23 ET
Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)
TipRanksApr 3 07:06 ET
Sutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipeline
TipRanksApr 3 00:35 ET
Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
Yahoo FinanceApr 2 15:13 ET
What's Going On With Sutro Biopharma (STRO) Stock?
Sutro Biopharma Inc (NASDAQ:STRO) shares are trading lower by 2.8% to $5.18 during Tuesday's session after the company announced the pricing of an underwritten offering of 14,478,764 shares of its com
BenzingaApr 2 12:46 ET
Sutro Biopharma Secures Major Deal With Ipsen for STRO-003
TipRanksApr 2 06:23 ET
Express News | Sutro Biopharma Priced An Underwritten Offering Of 14.48M Shares At $5.18/Share, With Gross Proceeds Of Approximately $75M
Moomoo 24/7Apr 2 06:22 ET
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors
Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.
GlobeNewswireApr 2 01:00 ET
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., April 2, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conj
Sutro BiopharmaApr 2 00:00 ET
Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech Investors
TipRanksApr 1 01:52 ET
Express News | Sutro Biopharma Shares Are Trading Higher After Oppenheimer Maintained Its Outperform Rating and $10 Price Target on the Stock. The Company Recently Reported 2023 Financial Results
Moomoo 24/7Mar 28 11:30 ET
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
BenzingaMar 28 11:00 ET
VERI, CHEK and MESO Are Among Pre Market Gainers
Seeking AlphaMar 27 08:24 ET
Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)
TipRanksMar 27 07:50 ET
Express News | Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Moomoo 24/7Mar 27 07:41 ET
No Data
No Data